The FDA decision on Roche Holding Ltd.’s (RHHBY.OB) investigational drug Ocrevus, proposed for the treatment of both relapsing and primary progressive forms of multiple sclerosis, is scheduled for March 28, 2017.The decision was supposed to have been announced late last December, but it got postponed by 3 months as a result of the submission of additional data by Roche regarding the commercial manufacturing process of Ocrevus, which required additional time for FDA review. If approved, Ocrevus could have peak sales in the range of $2.6 billion to $3.8 billion, say some analysts.